JO
BTAI icon

John Overdeck’s BioXcel Therapeutics BTAI Stock Holding History

John Overdeck’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-27,029
Closed -$1.09M – 3158
2023
Q3 		$1.09M Buy
+27,029
New +$2.73M ﹤0.01% 1879
2023
Q2 		– Sell
-13,624
Closed -$4.07M – 3026
2023
Q1 		$4.07M Buy
+13,624
New +$5.82M 0.01% 1011
2022
Q4 		– Sell
-3,531
Closed -$668K – 2816
2022
Q3 		$668K Sell
3,531
-5,236
-60% -$1.22M ﹤0.01% 1643
2022
Q2 		$1.85M Buy
8,767
+3,800
+77% +$799K 0.01% 1245
2022
Q1 		$1.66M Buy
4,967
+2,914
+142% +$845K ﹤0.01% 1446
2021
Q4 		$668K Sell
2,053
-1,148
-36% -$493K ﹤0.01% 2948
2021
Q3 		$1.55M Sell
3,201
-4,984
-61% -$2.19M ﹤0.01% 2213
2021
Q2 		$3.81M Sell
8,185
-1,148
-12% -$626K 0.01% 1371
2021
Q1 		$6.45M Buy
+9,333
New +$7.51M 0.02% 915
2020
Q4 		– Sell
-1,075
Closed -$746K – 3352
2020
Q3 		$746K Sell
1,075
-3,175
-75% -$2.38M ﹤0.01% 1963
2020
Q2 		$3.6M Buy
+4,250
New +$2.77M 0.02% 805

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

John Overdeck's BTAI Position: Q4 2023 in Review

John Overdeck sold out of BioXcel Therapeutics (BTAI) in Q4 2023, closing a stake of 27,029 shares — an estimated $1.09M sold.

John Overdeck first reported a position in BTAI in Q2 2020 and held it in 11 quarters. The position peaked at $6.45M in Q1 2021. 73 funds tracked by Wall St. Rank hold BTAI as of Q4 2023.

  • John Overdeck reported no remaining BioXcel Therapeutics position as of Q4 2023 after selling out during the quarter.
  • John Overdeck sold 27,029 BioXcel Therapeutics shares in Q4 2023, an estimated $1.09M.
  • John Overdeck first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 11 quarters.
  • John Overdeck's BioXcel Therapeutics position peaked at $6.45M in Q1 2021.
  • 73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2023.

Based on Two Sigma Investments's 13F filing for Q4 2023, filed 14 Feb 2024.